Hos henholdsvis 70% og 30% af patienterne var indholdet af virus under 500 kopier/ ml efter 48 ugers behandling.  Den tredje undersøgelse viste, at der var flere patienter i Stocrin- gruppen end i placebogruppen, der havde et virusindhold på under 400 kopier/ ml efter 24 uger.
70% and 30% of the patients, respectively, had viral loads below 500 copies/ ml after 48 weeks;  the third study showed that more patients receiving Stocrin had viral loads below 400 copies/ ml than those taking placebo after 24 weeks.